Skip to main content

Table 2 Literature review of patients who developed severe adverse events during telbivudine treatment

From: Rhabdomyolysis, lactic acidosis, and multiple organ failure during telbivudine treatment for hepatitis B: a case report and review of the literature

Patient number

Age (years)

Adverse effect

Liver condition

Tx time (months)

Peak CK (U/L)

Peak lactate (mmol/L)

Prognosis

Reference

1

27

Myopathy

CHB

3

3243

Resolved

[4]

2

67

Myopathy

CHB

20

4775

Resolved

[14]

3

25

Myopathy

CHB

6

1614

Resolved

[15]

4

28

Myopathy

CHB

9

788

Resolved

[16]

5

25

Myopathy

CHB

13

2992

Resolved

[16]

6

68

Myopathy

CHB

2

237

Resolved

[17]

7

35

Rhabdomyolysis, lactic acidosis

CHB

11

3683

> 12.0

Resolved

[6]

8

26

lactic acidosis

CHB

12

4151

11.3

Resolved

[18]

9

30

Rhabdomyolysis, lactic acidosis, organ failure

CHB

11

8050

> 20.0

Resolved

This paper

10

48

Rhabdomyolysis, metabolic acidosis, organ failure

Cirrhosis

9

3246

Death

[5]

  1. CHB chronic hepatitis B, CK creatine kinase, Tx treatment, lactate mmol/L × 9.608 = mg/dL